New hope for Tough-to-Treat cervical cancer with cheaper drug combo

This study is testing whether adding a more affordable immunotherapy drug called Toripalimab to standard chemoradiotherapy can better control high-risk, locally advanced cervical cancer. It will involve about 130 patients in China who have not had prior treatment. The main goal is to see if this combination improves the two-year survival rate without the cancer getting worse, while also being more accessible than similar, more expensive treatments.